Context: Postpartum depression (PPD) is common and has serious implications for the mother and her newborn infant. A possible link between placental corticotropin-releasing hormone (pCRH) and PPD incidence has been hypothesized, but empirical evidence is lacking.
P OSTPARTUM MOOD DISORders range from the mild and common postpartum "blues" to much rarer incidences of severe postpartum psychosis. 1 The most commonly studied postpartum mood disorder is postpartum depression (PPD), which is similar to major depressive disorder but has its onset within the first 4 weeks (International Statistical Classification of Diseases, 10th Revision) 2 to 6 weeks (DSM-IV) 3 after delivery. Postpartum depression not only influences the well-being of the new mother but also has adverse effects on the cognitive and behavioral development of her infant. 4 Reports of PPD prevalence vary widely; a recent meta-analysis estimates it at 19 .2% (7.1% for major PPD alone) within the first 3 months post partum. 5 The high incidence and severe consequences of PPD make the identification of women at risk an important research goal. The most consistently identified risk factors include previous PPD; a history of depression, anxiety, stress, and depression during pregnancy; stressful life events; lack of social support; and low self-esteem 6, 7 ; however, these risk factors explain only a portion of the variance in the incidence of PPD. Endocrine risk factors for PPD have been identified as well, including changes in reproductive hormones during pregnancy, a history of premenstrual syndrome, and a history of oral contraceptiveinduced mood changes. [8] [9] [10] Little research interest has been directed toward the role of corticotropinreleasing hormone (CRH), a 41-amino acid neuropeptide central in the regula-tion of the hypothalamic-pituitary-adrenal (HPA) axis, 11 as a potential predictor of PPD. 12 This is surprising because several lines of evidence suggest the possibility that increased CRH may be a risk factor for PPD. First, CRH plays an important role in the etiology of depression in the nonpregnant state. 13 For example, depressed patients are more likely to have an increased number of hypothalamic CRH neurons, and these neurons tend to be hyperactive. 14, 15 This evidence has led to the development of a CRH hypothesis of depression, suggesting that the hyperactivity of CRH neurons and the HPA axis may trigger depressive symptoms. 16 Second, pregnancy is characterized by marked changes in maternal HPA axis regulation. In the central nervous system, CRH is produced in the paraventricular nucleus of the hypothalamus and released into the median eminence, a local portal system connecting the hypothalamus with the pituitary, where CRH stimulates the release of adrenocorticotropic hormone (ACTH). Binding by ACTH causes the adrenal cortex to release the glucocorticoid cortisol. 17 During pregnancy, CRH is also produced by the placenta and, unlike CRH of hypothalamic origin, is detectable in maternalperipheralblood. 18, 19 Placental(pCRH)andhypothalamic CRH are similar with regard to their structure, immunoreactivity, and bioactivity. 20, 21 However, in contrast to the role of cortisol in the negative feedback regulation of the HPA axis, cortisol stimulates CRH production in the placenta. As a result, levels of pCRH in maternal plasma increase exponentially throughout pregnancy 18, 22 and reach levels similar to those of hypothalamic CRH in the median eminence under conditions of acute stress. 23 The sudden disappearance of the placenta after delivery results in a sharp drop of pCRH levels. The postpartum period is therefore characterized by pCRH withdrawal, resulting in transient suppression of hypothalamic CRH release and HPA axis dysregulation. It has been suggested that this may explain the occurrence of postpartum depressive disorders. [24] [25] [26] [27] [28] [29] Finally, there are marked interindividual differences in the trajectories of pCRH throughout pregnancy. 22 It has been demonstrated that accelerated trajectories of pCRH are associated with race/ethnicity 30 and preterm birth 22, [31] [32] [33] [34] ; are implicated in pregnancy complications such as preeclampsia, [35] [36] [37] fetal growth retardation, 38 and diminished umbilical artery blood flow 39 ; and have consequences for the developing infant, including lower newborn physical and neuromuscular maturity 40 and increased irritability. 41 Because of the established association between CRH and depression, accelerated increases in pCRH throughout pregnancy may also serve as a potential early marker to identify women at high risk for PPD. It is the goal of the present study to address this possibility.
METHODS

PARTICIPANTS
One hundred pregnant women with a singleton, intrauterine pregnancy were selected from a larger sample 30, [40] [41] [42] that was recruited in a longitudinal study at Cedars-Sinai Medical Center and the University of California, Irvine, Medical Center. In this study, subjects with conditions known to affect HPA axis function, subjects with alcohol or other drug abuse within 6 months before the index pregnancy, and non-English-speaking subjects were excluded from participation.
The present sample consisted of the 100 women with complete data for pCRH and depressive symptoms. Mean (SD) age at delivery was 31.2 (5.3) years. The ethnic composition was 54% non-Hispanic white, 22% Hispanic white, 12% Asian, 7% African American, and 5% multiethnic or other. Most women were married (79%), had graduated from high school (97%), and were college graduates (52%). The annual household income varied from $5000 to more than $100 000, and median income was in the range of $80 000 to $90 000. All pregnancies resulted in live births, and 53 girls and 47 boys were delivered. Deliveries were 72% vaginal and 28% cesarean section. Mean (SD) infant birth weight was 3514 (469) g (range, 2340-4450 g), and gestational length at term was 39.4 (1.3) weeks (range, 36.57-42.0 weeks). Because completion of the full study was an inclusion criterion, and because the last study visit occurred around 37 weeks' gestational age (GA), most women had full-term infants (97% had a gestational length Ͼ37 weeks), and no woman delivered before 36.6 weeks' GA. Most women had no previous live-born children (61%).
OVERALL PROCEDURE
Blood samples were obtained at a mean (SD) of 15.3 (0.92), 19.2 (0.72), 25.0 (0.94), 31.0 (0.76), and 36.7 (0.70) weeks' GA for assessment of pCRH, cortisol, and ACTH. Depressive symptoms were assessed at the last 4 time points during pregnancy and again at the postpartum visit (mean [SD], 8.7 [2.9] weeks). Written informed consent was obtained from all women before participation. This protocol was approved by the institutional review boards of the participating institutions.
HORMONE MEASURES
A 25-mL blood sample was obtained by antecubital venipuncture. Samples were drawn into chilled EDTA-treated test tubes (Vacutainers; Becton Dickinson and Company, Sumter, South Carolina) and spun for 15 minutes at 2000g. The plasma was then decanted into polypropylene tubes containing 500kallikrein inhibitor units/mL of aprotinin (Sigma-Aldrich Corp, St Louis, Missouri) and stored at −70°C until assayed.
The concentration of total CRH was determined by means of radioimmunoassay using antiserum directed at human CRH (Bachem Peninsula Laboratories, San Carlos, California). Plasma samples (1-2 mL) were extracted with 3 volumes of ice-cold methanol, mixed, allowed to stand for 10 minutes at 4°C, and then centrifuged (20 minutes, 1700g, 4°C). 43 The pellets were washed with 0.5 mL of methanol, and the combined supernatants dried in a concentrator (SpeedVac; Savant Instruments, Holbrook, New York). Reconstituted samples were incubated (100 µL/assay tube) with antiserum (100 µL/assay tube) for 48 hours at 4°C followed by an overnight incubation with iodine 125 -labeled CRH at 4°C. Labeled and unlabeled CRH samples were collected by means of immunoprecipitation, and the aspirated pellets were counted using a gamma counter (Isoflex; ICN Biomedical, Costa Mesa, California). Crossreactivity was less than 0.01 for ovine CRH, 36% for bovine CRH, and nondetectable for human ACTH. Intra-assay and interassay coefficients of variance were 5% and 15%, respectively. Using this technique, our laboratory has reliably detected pCRH at as early as 15 weeks' GA. 30, [40] [41] [42] Plasma levels of ACTH were measured by a solid-phase 2-site immunoradiometric assay using human ACTH antibodies with nonsignificant cross-reactivity with ␤-endorphin and ACTH fragments, and with reported detection limits of 1.0 pg/mL (Nichols Institute Diagnostics, San Juan Capistrano, Califor-nia) (to convert ACTH to picomoles per liter, multiply by 0.22). Briefly, 200-µL samples combined with 100 µL of ACTHlabeled antibody and a coated bead were incubated at room temperature for a mean (SD) of 20 (1) hours. The bound radiolabeled antibody complex was quantified using the gamma counter. Intra-assay and interassay coefficients of variation were 4.4% and 10.8%, respectively.
Plasma cortisol levels were determined using a competitive antibody-coated tube radioimmunoassay with reported sensitivity of 0.22 µg/dL (American Laboratory Products Company, Windham, New Hampshire) (to convert cortisol to nanomoles per liter, multiply by 27.588). Plasma samples (25 µL) were incubated with 500 µL of 125 I-labeled cortisol in antibody-coated tubes for 45 minutes in a 37°C water bath. The aspirated radiolabeled antibody-bound labeled tubes were counted on a gamma counter. Cross-reactivities of the cortisol assay were less than 5% with 11deoxycortisol, cortisone, and prednisone, and less than 1% with other steroids. Intra-assay and interassay coefficients of variation were 7% and 11%, respectively.
Concentrations of CRH, ACTH, and cortisol were interpolated from standard curves computed by a 4-parameter logistics program. 44
ASSESSMENT OF DEPRESSIVE SYMPTOMS
Depressive symptoms were assessed 4 times during pregnancy with a 9-item version of the Center for Epidemiological Studies-Depression Scale (CES-D). 45 On a 4-point scale, participants indicated how often they experienced a symptom during the past week. Because validation analyses show higher associations with the Structured Interview for DSM-III-R when items are rescored into a bivariate score, 45 each item was scored 0 if option 0 or 1 was endorsed, and was scored 1 if option 2 or 3 was endorsed. Bivariate scores ranged between 0 and 9, with a suggested cutoff score of 4 or more. This scale has good internal consistency (Kuder-Richardson formula 20, 0.87), and the scores correlate highly with the original scale (r=0.97).
At the postpartum visit, participants completed the 10item Edinburgh Postnatal Depression Scale (EPDS), 46 a scale specifically developed to assess postpartum depressive symptoms. Participants indicated how often they experienced a symptom in the past week on a 4-point scale. Total scores ranged from 0 to 30. A cutoff score of 10 or more has been suggested by the authors of the EPDS for studies including minor depression 46 and has been confirmed in other studies. 47 The scale has good reliability (split-half, 0.88; standardized ␣=.87). 46 
STATISTICAL ANALYSIS
All pCRH, cortisol, and ACTH levels were log transformed to reduce skewness. Pearson product moment correlations were performed to test for associations between relevant variables. The time of day of the blood draw was covaried when appropriate and in no case changed the significance of the results.
Variables that were significantly correlated with PPD symptoms were included in a stepwise linear regression model, and the model fit (adjusted R 2 ), the change in R 2 , and the regression coefficient ␤ are reported. Emerging significant predictors were included in a hierarchical linear regression model to assess the unique and separate contributions of each variable. A series of ancillary analyses (2-tailed, independent samples t tests and 2 tests) revealed no evidence that sociodemographic (ethnicity, marital status, education, and household income) or pregnancy-related variables (birth weight, length of gestation, infant sex, mode of delivery, and parity) were significantly associated with PPD symptoms (for all associations, 2 Ͻ9. 33 The sample was then divided into women with and without PPD symptoms ( Table 1 lists the sample characteristics). Receiver operating characteristic (ROC) curves were computed to assess sensitivity and specificity of relevant variables as potential diagnostic markers for PPD symptoms. For this analysis, non-log-transformed pCRH values were used to provide practical guidelines for actual pCRH cutoff scores. The areas under the ROC curve (AUCs) were computed to compare the usefulness of each diagnostic test. The AUC values can range from 0.5 to 1.0, with 1.0 indicating a perfect test. The Youden index (sensitivityϩ[specificity−1]) was computed to obtain an optimal cutoff score. The Youden index can range from −1 to 1, with 1 indicating a perfect test. 48, 49 Positive and negative predictive values (PPV and NPV, respectively) were computed to express the probability that PPD is present when the test is positive (PPV) and absent when the test is negative (NPV) at the optimal cutoff.
To estimate when differences in pCRH emerge as a predictor of PPD symptoms, multilevel modeling techniques (HLM 6) 50 were used. First, an unconditional means model was computed to assess how much variance in pCRH can be attributed to betweensubject (99.6%) and within-subject (0.4%) variation. Two unconditional growth models were then computed to assess the linear (coefficient, 18.48; SE, 1.07 [PϽ.001]) and quadratic (0.85; 0.13 [PϽ.001]) effects of time (level 1 predictor) on pCRH, which explained 68.9% and 80.4% of the variance, respectively. A comparison of the deviance scores revealed that the quadratic model fit the data significantly better than the linear model ( 2 3 =137.04 [PϽ.001]). Postpartum depressive symptoms (coded 0 for no and 1 for yes) were then included as a level 2 predictor into a series of quadratic models that tested differences in the intercept and the instantaneous rate of change at each GA within the range of actual pCRH assessments available (12-39 weeks' GA). The error term was allowed to vary randomly in each equation.
RESULTS
DESCRIPTIVES
Consistent with earlier reports, pCRH increased significantly throughout pregnancy (F 3.4,332.5 =586.83 [PϽ.001]; 2 = 0.86). Likewise, significant increases in cortisol ( 
PREDICTORS OF PPD SYMPTOMS
At no time during pregnancy were any of the endocrine measures significantly associated with concurrent depressive symptoms (pCRH, r=0.02 to r=0.15 [PϾ.14 for all comparisons]; ACTH, r=−0.01 to r=−0.16 [PϾ.12 for all comparisons]; and cortisol, r = −0.002 to r = −0.06 [P Ͼ .53 for all comparisons]). However, when pCRH, ACTH, cortisol, and CES-D scores at each time point during pregnancy were correlated with PPD symptoms (Table 2), significant correlations emerged for pCRH at 25 and 31 weeks' GA, for ACTH at 25 weeks' GA, and for CES-D scores at 19, 25, 31, and 37 weeks' GA. The 2 strongest associations (pCRH and CES-D scores at 25 weeks' GA) are depicted in Figure 1 . These correlational analyses suggest no significant association between HPA axis hormones and depressive symptoms when assessed concurrently and provide evidence that HPA axis hormones (in midpregnancy) and depressive symptoms (throughout pregnancy) are significant predictors of PPD symptoms.
To assess which variables are the strongest predictors of PPD symptoms, all variables that were significantly correlated with PPD symptoms (pCRH at 25 and 31 weeks' GA, ACTH at 25 weeks' GA, and CES-D scores at 19, 25, 31, and 37 weeks' GA) were included in a stepwise linear regression. Elevated pCRH at 25 weeks' GA emerged as the strongest predictor for PPD symptoms (step 1: R 2 =0.21; ␤=0.46 [PϽ .001]). The prediction of PPD symptoms was improved by including CES-D scores at 25 weeks' GA into the model, accounting for 7% additional variance (step 2: ␤ CRH = 0.42; ␤ CES-D = 0.26 [P Ͻ.001]), whereas the influence of all other variables was not statistically significant. Because pCRH at 25 weeks' GA emerged as the best predictor, a hierarchical linear regression was performed to test the unique predictive value of pCRH on PPD symptoms after controlling for CES-D scores at this time point. After CES-D scores were entered into the model in step 1, pCRH was still a significant and independent predictor of PPD symptoms (step 2: R 2 change=0.17 [PϽ.001]). This further indicates that pCRH and CES-D scores explain different portions of the variance in the risk of developing PPD symptoms.
pCRH LEVELS AND CES-D SCORES AS DIAGNOSTIC TESTS FOR PPD SYMPTOMS
To test whether pCRH and CES-D scores at 25 weeks' GA may be useful diagnostic tests for PPD symptoms, the sample was divided into women with (n=16) and without (n=84) PPD symptoms. An ROC curve for pCRH was computed, and the AUC was 0.78 (95% confidence interval [CI], 0.65-0.91 [P=.001]), suggesting that at this time point pCRH is a moderate predictor of PPD (Figure 2A) Figure 2B . The ROC analyses for CES-D scores at 25 weeks' GA showed that this measure was a similarly strong predictor of PPD symptoms (AUC=0.77 [P=.001]; 95% CI, 0.65-0.89) (Figure 3A) , confirming previous research that identified depression during pregnancy as an important predictor. In contrast to the ROC analyses for pCRH levels, the AUCs for depressive symptoms were significant for all other time points (19 weeks, 0.80 [P Ͻ.001]; 31 weeks, 0.71 [P=.009]; 37 weeks, 0.69 [P=.02]), suggesting that the predictive value of depressive symptoms is not specific to midpregnancy. At 25 weeks' GA, the op-timal CES-D cutoff score (Youden index, 0.45) was 1.5. With this cutoff (ie, an actual score of Ն2 because CES-D scores have no decimals), 87.5% (95% CI, 61.6%-98.1%) of women with PPD symptoms would have been correctly identified; however, 42.9% (95% CI, 32.1%-54.1%) of women without future PPD symptoms would have been misclassified. The PPV was 28.0% (95% CI, 16.2%-42.5%) and the NPV was 96.0% (95% CI, 86.3%-99.4%). Sensitivity and specificity for all possible cutoff scores are shown in Figure 3B . At the ideal cutoff points, the CES-D is the more sensitive diagnostic test (CES-D score vs pCRH, 88% vs 75%), whereas pCRH is more specific (pCRH vs CES-D score, 76% vs 57%) for the detection of PPD symptoms.
TIME-SENSITIVE PERIODS FOR THE PREDICTION OF PPD SYMPTOMS
The analyses in the previous section suggest that the predictive value of pCRH for PPD symptoms may be limited to midpregnancy. With hierarchical linear modeling analyses, it is possible to model increases in pCRH throughout pregnancy and to estimate (1) the time range during which the instantaneous rate of change in pCRH predicts PPD symptoms and (2) the earliest time during gestation that differences in pCRH predict PPD symptoms. The growth curve analysis suggests that the instantaneous rate of change in pCRH in women with PPD symptoms is significantly accelerated from 23 to 26 . These data suggest that it is the rate of change in pCRH at about 25 weeks' GA, the time when differences in pCRH start to emerge, that makes some women more vulnerable to the development of PPD symptoms, and that pCRH in these women then remains at an accelerated trajectory until delivery.
COMMENT
These data are, to our knowledge, the first to suggest a sensitive period in midpregnancy during which pCRH, as measured in maternal plasma, is a moderate and independent predictor of PPD symptoms. We propose that pCRH during this period may serve as a sensitive and specific early diagnostic test to identify women at high risk for developing PPD symptoms. Our data also suggest that the predictive power of pCRH during this period can be further increased by assessing midpregnancy depressive symptoms.
Our data indicate that pCRH is a possible diagnostic tool to identify women at risk for the development of PPD symptoms. This is plausible from a neuroendocrine point of view. The postpartum period is characterized by a transient blunting of hypothalamic CRH secretion, which has been implicated in the pathophysiologic mechanisms of PPD. 25, 28 Consistent with this view, it has been shown that women who develop PPD show a more pronounced and longer-lasting suppression of ACTH responses to stimulation with exogenous (ovine) CRH within the first 12 weeks post partum, compared with women who remain euthymic. 26 Our data now provide evidence that the HPA-placental system is already dysregulated during pregnancy among women at risk for PPD symptoms, such that they show accelerated pCRH increases. This is clinically relevant because the assessment of pCRH in maternal blood may provide a method to identify women at risk for PPD symptoms, months before symptoms occur.
Placental CRH in this study was a moderately sensitive and specific marker for PPD symptoms that allows for the correct identification of 75% of women with future PPD symptoms, and at the same time was characterized by a low misclassification rate (24%). The strength of pCRH as a diagnostic test for an early detection of PPD symptoms is indicated by an AUC of 0.78 at 25 weeks' GA. This association is high given that (1) a single endocrine marker was used to predict PPD symptoms and (2) the AUC for depressive symptoms, which are among the strongest and most consistently identified predictors of PPD in the previous literature, 6, 7 is almost identical (0.77).
Our data also show that elevated pCRH but not cortisol or ACTH is a significant predictor of PPD symptoms (except for a correlation between ACTH at 25 weeks' GA and PPD symptoms that did not remain significant in the regression analyses). Few studies have investigated the link between cortisol or ACTH during pregnancy and PPD symptoms. Results are mixed, but the clearest evidence for an existing association comes from studies that have assessed the stimulated activity of these hormones. 26, [51] [52] [53] In our study, however, baseline measures of cortisol and ACTH were used, which may explain the lack of association we found.
Remarkably, pCRH is an independent predictor of PPD symptoms. Placental CRH at 25 weeks' GA has unique and significant predictive value for PPD symptoms, even after controlling for concurrent depressive symptoms. It indicates that assessing pCRH allows the identification of women at risk for developing PPD symptoms who would not be identified on the basis of self-reports of depressive symptoms during pregnancy. This is plausible because hormone measures are independent of a woman's willingness to disclose feelings of depression. Thus, the combined assessment of both markers may be an ideal strategy for identifying women at risk for the development of PPD symptoms.
Depressive symptoms at each time point during gestation are associated with PPD symptoms; however, the predictive value of pCRH for PPD symptoms is time sensitive and is maximized during midpregnancy (23-26 weeks' GA). The emergence of pCRH as a predictor of PPD symptoms around this time roughly coincides with a marked surge in pCRH. 22, 42 Detrimental influences at the time of this initial surge may slightly accelerate the exponential trajectory of pCRH, resulting in marked differences in pCRH toward the end of gestation. We do not know which factors may precipitate the surge in pCRH, but some evidence suggests an association between elevated cortisol early in pregnancy and increased pCRH late in pregnancy. 42 
